The implications of using more accurate estimates of GFR, such as eGFRcr-cys, for cancer treatment safety and clinical outcomes would benefit from prospective confirmation, which would require routine testing of cystatin C in clinical cancer trials. The gene discussed is CST3; the disease is cancer.